167 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
further characterization of frataxin PD at the 25 mg dose. The OLE study is evaluating the long-term safety as well as frataxin levels following daily … 50% of the average healthy volunteer level.
The long-term safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
of Ambulation
Completed Ph 2 Dose Exploration Study (25 & 50 mg Cohorts) Goal: Further characterize PK/PD and assess safety to inform long-term dose … Dose Cohort 1: 25 mg Cohort 2: 50 mg Key Endpoints Frataxin levels in peripheral tissue, PK, safety and tolerability; other exploratory endpoints
8-K
EX-99.2
m0cj97wi7zz3ms 0t088
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
8-K
EX-99.1
f9ihy32xm os621
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
PRE 14A
gl3nap2yz7yaw o03pip
12 Apr 24
Preliminary proxy
6:06am
8-K
EX-99.1
c682 5g28cedk6m5o
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
8-K
EX-99.1
kqhdorl
11 Mar 24
Other Events
4:09pm
8-K
EX-99.3
wdw2 owp3
11 Mar 24
Other Events
4:09pm
8-K
EX-99.2
g28euk57gyai ru7s
11 Mar 24
Other Events
4:09pm
8-K
EX-1.1
pwsdkd0sy0p8uaja
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
6e36azdia qywrst
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
ua3vf4
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.2
1vnb6
12 Feb 24
Results of Operations and Financial Condition
7:03am